Study of the effectiveness and safety of the drug Mexol Fort 250 as part of consecutive therapy in patients with a hemisphere ischemic stroke in acute and early recovery periods

Authors:
M.A. Loskutnikov, M.A. Domashenko, T.M. Vakin, I.A. Trushina, V.I. Konstantinov, O.S. Proskuryakova, E.P. Shchukina

ANO "Central Clinical Medicine-Sanitary Part", Magnitogorsk, Russia

Place of publication:
S.S. KORSAKOV JOURNAL OF NEUROLOGY AND PSYCHIATRY, 2020, Vol. 120, No. 10

Abstract:
Objective of the study. To evaluate the efficacy and safety of sequential therapy with Mexidol (solution for intravenous and intramuscular administration) and Mexidol FORTE 250 (film-coated tablets) in patients with hemispheric ischemic stroke in the acute and early recovery periods. Material and methods. At the end of the therapy course, the dynamics of the modified Rankin Scale (mRS), the results of testing on the National Institutes of Health Stroke Scale (NIHSS), the Barthel Index (BI), the Montreal Cognitive Assessment (MoCa), the Beck Demographic Inventory (BDI), and the Quality of Life Questionnaire (EQ-5D) were assessed. Results and conclusion. Sequential long-term therapy with Mexidol at a dosage of 500 mg/day for 14 days (saturation phase) and Mexidol Forte 250 at 250 mg 3 times daily for 60 days (therapeutic effect maximization phase) provides additional opportunities for more complete recovery in the acute and early recovery periods of hemispheric stroke (improves quality of life and improves motor and cognitive function). Key words: hemispheric ischemic stroke, Mexidol Forte 250, acute and early recovery periods, quality of life.